FATE: Fate Pharma P/S Multiple

Brandmark of Fate Pharma (FATE)

The revenue multiple dynamics reported by the GURU.Markets platform confirm that the valuation of Fate Therapeutics, Inc. (FATE) depends on clinical trial outcomes. Growth is supported by iPSC-based NK-cell synthesis technologies and strategic alliances with pharma behemoths to combat tumors. Meanwhile, the 34.20 value serves as a baseline indicator of market expectations, linking current market capitalization to the company's actual sales volumes.

FATE - Fate Therapeutics Corp P/S Multiple over the range 07/04/2022 - 11/13/2026

Fate Therapeutics Corp (FATE) - metric breakdowns and financial figures

- share price and expert price forecast:
Quote Chart fatetherapeutics.com|FATE - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Fate Therapeutics Corp|FATE - Real Price to Acquire Entire Company
- balance sheet equity data:
Book Price of a Share Fate Therapeutics|FATE - Book Capitalization|Market-to-Book Ratio fatetherapeutics.com|FATE - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Fate Therapeutics, Inc.|FATE - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Fate Pharma|FATE - Company Aggregate Debts|Debt to Net Assets Ratio Fate Therapeutics Corp|FATE - Company Long-Term Debts|Short-Term Debt Fate Therapeutics|Intermediate Coverage Ratio fatetherapeutics.com
- earnings and market ratios statistics:
FATE - Net Profit|Projected Future Earnings Fate Therapeutics, Inc.|FATE - Price to Earnings Ratio|Price to Expected Earnings Ratio Fate Therapeutics Inc|FATE - PEG Multiple|Company Value to EBITDA Fate Therapeutics Corp|FATE - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Fate Therapeutics|FATE - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months fatetherapeutics.com|FATE - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Fate Therapeutics, Inc.
- issuer revenue and sales details:
FATE - Revenue and Sales Volume|Company Future Sales Volume fatetherapeutics.com|FATE - Price-to-Revenue Ratio|Market Cap to Expected Sales Ratio Fate Therapeutics Corp
General company analysis:fatetherapeutics.com, FATE
Finished products of Fate Therapeutics Inc

Investors must find a balance between operational risks and future returns, given that the Inertia platform establishes a long-term patent foundation for subsequent monetization. Analyzing the price-to-sales ratio allows for an assessment of the business's market value relative to its actual sales, identifying the risk of overpayment or signs of capital stagnation, which confirms the resilience of the technological profile of Fate Therapeutics, Inc. (FATE).

Competing companies

ONC: Price-to-Sales Ratio|P/S Multiple HALO (Halozyme)|P/S Multiple Revolution Medicines Inc RVMD|AAPG: Market Cap to Revenue|CG Oncology Therapeutics - Market Cap to Sales Volume|URGN: P/S Multiple|Price to Sales bicara.com (BCAX)|Market Cap to Revenue PSNL|ERAS: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue DCTH (Delcath)|Market Cap to Sales Volume YMAB|P/S Multiple AURA (Aura Biosciences, Inc.)|Market Capitalization-to-Revenue Ratio CADL|Accuray - P/S Multiple|Price to Sales SELLAS Life Sciences|Actuate Therapeutics, Inc (ACTU) - Price-to-Revenue Ratio|Citius Oncology Inc - Market Capitalization-to-Revenue Ratio|HURA (TuHURA Biosciences Inc.) - P/S Multiple|P/S Multiple protaratx.com|Price-to-Revenue Ratio Aadi Bioscience Inc (WHWK)|TCRX: Price-to-Sales Ratio|P/S Multiple CSBR (Champions Oncology, Inc.)|XBiotech Inc (XBIT) - Price to Sales|CVM: Market Cap to Revenue|OSTX - P/S Multiple|RADX (Radiopharm Theranostics) - Market Cap to Revenue|ARTV: Market Cap to Sales Volume|ANL (Adlai Nortye Ltd) - P/S Multiple|Veru Corporation (VERU) - Price-to-Revenue Coefficient|P/S Multiple TPST|Market Cap to Revenue xiliotx.com XLO|Price-to-Revenue Ratio Renovaro RENB|Price-to-Revenue Coefficient Mural Oncology PLC (MURA)|KAPA: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio OKUR (OnKure Therapeutics Inc)|GDTC: P/S Multiple|CRIS - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Apollomics Inc.|Market Cap to Revenue Ratio THAR (Tharimmune Inc)|P/S Multiple ADVB|Market Cap to Revenue Genprex Inc GNPX|Calidi Biotherapeutics, Inc. - Market Cap to Revenue|Price-to-Revenue Coefficient sunshinebiopharma.com (SBFM)|Xenetic Bio - P/S Multiple|Price-to-Sales Ratio SLRX|PPBT: P/S Multiple|American Oncology Network, Inc. (AONC) - P/S Multiple|Market Cap to Revenue BGNE|CKPT (checkpointtx.com) - Market Cap to Sales Volume|P/S Multiple ELEV|ICAD - Price to Sales|P/S Multiple IKNA (Ikena Oncology)|NTBL - Market Cap to Revenue|Viracta - P/S Multiple|MOR - P/S Multiple|NAYA Biosciences Inc. (NAYA) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio AAPGV